What Is Clomiphene Used For? Approved Uses, Per the Label

Answer first: the approved indication

Clomiphene citrate is a prescription medicine in the United States, supplied as oral tablets under names including Clomid and Serophene. In the US prescribing information, it carries a single approved indication: the treatment of ovulatory dysfunction in women who desire pregnancy. The labeling frames that indication narrowly, directing that other impediments to achieving pregnancy be identified and addressed before clomiphene therapy is started, and it describes the patient groups in which ovulatory response has been most consistently observed, such as women with polycystic ovary syndrome and certain forms of secondary amenorrhea.

Labeling for clomiphene citrate products is revised periodically, and the revision date appears on the FDA-approved labeling for each specific product. Anyone who needs the exact current wording should read the approved labeling for the specific product and discuss it with a prescribing clinician.

This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any medicine, including clomiphene, is appropriate for a given person.

US label versions on DailyMed: Clomid (clomiphene citrate) tablets, prescribing information revised August 2023 (DailyMed). The current label for the specific product governs.

How the label indication is structured

Ovulatory dysfunction in women desiring pregnancy

The approved use is an ovulation induction use. Clomiphene is given to induce ovulation in women whose cycles are anovulatory or irregular and who are trying to conceive. The indication is tied to that goal, which is why the labeling emphasises confirming ovulatory dysfunction, excluding other causes of infertility, and monitoring the ovulatory response.

Pharmacologic class on the label

Clomiphene is classified pharmacologically as a selective estrogen receptor modulator. A review of selective estrogen receptor modulators described clomiphene among agents that act as estrogen receptor agonists in some tissues and antagonists in others, with the antiestrogenic effect at the hypothalamus and pituitary underlying its use in ovulation induction (PMID 12911186). A 2026 review of clomiphene citrate in the management of anovulation surveyed the proposed mechanisms, the outcomes reported across the literature, and the clinical challenges described by researchers in that setting (PMID 41863134).

Regulatory history of the indication

Clomiphene citrate has been an approved prescription medicine in the United States for several decades, and its indication has remained an ovulation induction indication throughout that period rather than expanding to other populations. The registration-era studies that supported the original approval are not part of the verified source set used for this page, so no claims are made here about their design or results. The evidence described below is post-approval comparative evidence: randomised trials, systematic reviews and narrative reviews published long after the indication was granted, which have refined how clomiphene is positioned against other ovulation induction agents rather than changing the wording of the approved use.

Two practical consequences follow from that history. First, the approved indication remains limited to women who desire pregnancy and have ovulatory dysfunction. Second, the large volume of published research on clomiphene in other populations has not, in itself, altered the label. Regulatory status and published evidence are separate things, and the label is the document that defines the approved use.

Published evidence in the approved setting

The studies summarised in the table below examined clomiphene citrate in ovulation induction and related fertility care. Each entry names what researchers reported, with the PubMed record linked alongside.

What that body of work does and does not show

Taken together, these publications describe clomiphene as a long-established oral agent for ovulation induction that has been compared head to head with alternatives. The 2014 randomised trial in polycystic ovary syndrome is the most frequently cited comparison and reported an advantage for letrozole on live birth in that population (PMID 25006718), while reviews of anovulation management have continued to describe clomiphene as a widely used option with recognised clinical challenges (PMID 41863134). None of these publications changes the approved indication, and none of them substitutes for an individual assessment by a prescribing clinician.

A short note on uses outside the approved indication

A substantial literature has examined clomiphene citrate in men, and that use is not an approved indication in the United States. A 2023 systematic review and meta-analysis pooled studies of clomiphene citrate in male infertility and reported on hormonal and semen parameter outcomes across those studies (PMID 36680549); a 2022 study examined testosterone kinetics in hypogonadal men receiving clomiphene (PMID 35577998); and a 2018 review discussed clomiphene among approaches investigated for male hypogonadism (PMID 29886559). Enclomiphene citrate, the trans isomer studied as a separate product, has been described in a 2019 review as an investigational treatment for men with secondary hypogonadism (PMID 31063005). These are research and off-label contexts, not approved uses of clomiphene citrate.

Adverse Events: What Studies Report

Adverse event information for clomiphene citrate appears both in the approved labeling and in published trials. In the 2014 randomised comparison in polycystic ovary syndrome, researchers reported that hot flushes occurred more commonly among women assigned to clomiphene, while fatigue and dizziness were reported more often in the letrozole group (PMID 25006718). That trial also reported on multiple gestation and pregnancy loss outcomes in both treatment groups (PMID 25006718).

Review articles have discussed the practical limitations that accompany ovulation induction with clomiphene, including the phenomenon researchers describe as clomiphene resistance and the challenges reported in clinical management of anovulation (PMID 41863134). Broader ovulation induction reviews have placed those considerations alongside monitoring practices used in fertility care (PMID 21185488). The full adverse reaction list, contraindications and warnings sit in the approved labeling and should be reviewed with a prescribing clinician rather than inferred from any single study.

Questions a prescribing clinician answers

• Whether an individual situation matches the approved indication for ovulatory dysfunction in a woman desiring pregnancy.
• What evaluation is appropriate before any ovulation induction medicine is considered.
• How clomiphene compares with alternatives for a specific diagnosis, in light of trial evidence such as the 2014 polycystic ovary syndrome comparison (PMID 25006718).
• What monitoring is used and what contraindications or warnings apply in the current approved labeling.
• How any use outside the approved indication would be classified and documented.

No dosing information appears on this page, and nothing here describes how any medicine should be used. For background on clomiphene chemistry, mechanism and the wider research literature, see the topic hub at /learn/clomiphene/.

References

• Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (The New England Journal of Medicine, 2014)
• Tamoxifen versus clomiphene citrate for ovulation induction in infertile women (European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2018)
• Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome (Journal of Clinical Pharmacy and Therapeutics, 2022)
• Minimal stimulation using gonadotropin combined with clomiphene citrate or letrozole for intrauterine insemination (Yonsei Medical Journal, 2015)
• Evidence-based approach to unexplained infertility: a systematic review (Fertility and Sterility, 2016)
• Induction of ovulation (Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 2010)
• Clomiphene citrate in the management of anovulation: a review of mechanisms, outcomes, and clinical challenges (Gynecological Endocrinology, 2026)
• Selective estrogen receptor modulators (Southern Medical Journal, 2003)
• Clomiphene citrate for male infertility: A systematic review and meta-analysis (Andrology, 2023)
• Testosterone kinetics on hypogonadal men under clomiphene (International Urology and Nephrology, 2022)
• Novel Therapy for Male Hypogonadism (Current Urology Reports, 2018)
• Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism (Expert Review of Endocrinology & Metabolism, 2019)